Sebum Metabolomics and Lipidomics for Clinical Applications

Prior treatment

• Use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.
• Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.
• Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.
• Participants Receiving Dermatological Treatments or Using Skincare Products
• Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.
• Use of lotions, sunscreen, or other skincare products that may affect skin condition within 12 hours prior to sampling.

Other illness

• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
• Presence of acute or chronic skin diseases, or chronic systemic diseases.
• Any other conditions deemed unsuitable for participation by the principal investigator.
• Participants with Skin Diseases or Specific Skin Conditions
• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
• Severe disease that may compromise skin integrity or pose a risk to participant safety.
• Any other conditions deemed unsuitable for participation by the principal investigator.
• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
• Severe disease that may compromise skin integrity or pose a risk to participant safety.
• Any other conditions deemed unsuitable for participation by the principal investigator.
• Known allergy to Sebutape or similar adhesive tapes, or a history of related adverse reactions.
• Known allergy or adverse reactions to the study intervention drug (topical antibiotic ointment containing bacitracin, polymyxin B, and neomycin).
• Presence of visible skin disease, wounds, infection, inflammation, or other abnormal skin conditions at the sampling site.
• Any other conditions deemed unsuitable for participation by the principal investigator.

Other

• Healthy Participants Undergoing Short-term Antibiotic Intervention

• Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be in good health and suitable for participation.
• No diagnosed skin diseases or chronic systemic diseases.
• No use of medications or receipt of dermatological treatments that may affect sebum secretion or the skin microbiome within the past two weeks.
• Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.
• Diagnosed by a physician or clinically assessed as having one of the following:
  • Acne
  • Atopic dermatitis
  • Seborrheic dermatitis
  • Psoriasis
  • Other common skin diseases
  • Specific skin conditions (e.g., postmenopausal or aging-related skin changes)
• Individuals aged ≥20 years, regardless of sex or ethnicity, and assessed by the investigator to be suitable for participation.
• Participants who, based on clinical needs or daily routines, are currently using or are expected to use or receive any of the following:
  • Physician-prescribed topical dermatological medications
  • Physician-prescribed systemic therapies (oral or injectable)
  • Routine use of general skincare products
  • Physician-directed non-invasive dermatological treatments
• Individuals aged ≥20 years, regardless of sex or ethnicity.
• Assessed by the investigator to be healthy, with skin condition suitable for the intervention used in this study.

Criteria the registry did not label

• Healthy Participants